Nuveen’s CASI Pharmaceuticals CASI Stock Holding History

Nuveen’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-28,308	Closed	-$679K	–	3385
2021 Q1	$679K	Buy	28,308 +4,804	+20%	+$135K	﹤0.01%	3015
2020 Q4	$693K	Buy	23,504 +238	+1%	+$5.17K	﹤0.01%	2929
2020 Q3	$356K	Buy	23,266 +5,099	+28%	+$96K	﹤0.01%	3042
2020 Q2	$455K	Sell	18,167 -1,143	-6%	-$24.8K	﹤0.01%	2936
2020 Q1	$394K	Buy	19,310 +17	+0.1%	+$406	﹤0.01%	2853
2019 Q4	$596K	Sell	19,293 -133	-0.7%	-$4.31K	﹤0.01%	2865
2019 Q3	$649K	Sell	19,426 -1,076	-5%	-$34.5K	﹤0.01%	2864
2019 Q2	$656K	Buy	+20,502	New	+$655K	﹤0.01%	2909

Other funds holding CASI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

IACGFIA

IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen's CASI Position: Q2 2021 in Review

Nuveen sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 28,308 shares — an estimated $679K sold.

Nuveen first reported a position in CASI in Q2 2019 and held it in 8 quarters. The position peaked at $693K in Q4 2020. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

Nuveen reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Nuveen sold 28,308 CASI Pharmaceuticals shares in Q2 2021, an estimated $679K.
Nuveen first reported a position in CASI Pharmaceuticals in Q2 2019 and held it in 8 quarters.
Nuveen's CASI Pharmaceuticals position peaked at $693K in Q4 2020.
68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.